Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.
The FDA approved a new safety warning for Depo-Provera alerting patients to a possible risk for a type of brain tumor called ...
Stocktwits on MSN
Pfizer CEO eyes big push towards obesity drug development in 2026 after $10B Metsera acquisition
Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...
Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...
The FDA has approved a label change to Pfizer's contraceptive injection The US Food and Drug Administration (FDA) has approved a label change to Pfizer’s injectable contraceptive, Depo-Provera ...
Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...
Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback